Cover image of the article: Prevention of Venous Thromboembolism in Major Orthopedic Surgery: Bayesian Network Meta-Analysis of 21 Randomized Trials Evaluating Unfractionated Heparins, Low-Molecular Weight Heparins, and New Oral Anticoagulants

Image Credit:Int Cardiovasc Res J

Prevention of Venous Thromboembolism in Major Orthopedic Surgery: Bayesian Network Meta-Analysis of 21 Randomized Trials Evaluating Unfractionated Heparins, Low-Molecular Weight Heparins, and New Oral Anticoagulants

Authors

Andrea Messori1,*, Sabrina Trippoli1, Dario Maratea1, Valeria Fadda1, Claudio Marinai2
1HTA Unit, ESTAR, Regional Health Service, Firenze, Italy
2Department of Pharmaceutical Logistics, ESTAR, Regional Health Service, Firenze, Italy
*Corresponding Author: Corresponding author: Andrea Messori, HTA Unit, ESTAR, Regional Health Service, Firenze, Italy Email: andrea.messori.it@gmail.com

International Cardiovascular Research Journal:Vol. 9, issue 4; e10966
Published online:Dec 31, 2015
Article type:Brief Report
Received:Jan 02, 2015
Accepted:Apr 21, 2015
How to Cite:Messori A, Trippoli S, Maratea D, Fadda V, Marinai C. Prevention of Venous Thromboembolism in Major Orthopedic Surgery: Bayesian Network Meta-Analysis of 21 Randomized Trials Evaluating Unfractionated Heparins, Low-Molecular Weight Heparins, and New Oral Anticoagulants. Int Cardiovasc Res J. 2017;9(4):e10966. doi: https://doi.org/10.17795/icrj-9(4)238

Abstract

Background: In major orthopedic surgery, prevention of venous thromboembolism has been based on Unfractionated Heparins (UFHs) over the past decades, then on Low-Molecular Weight Heparins (LMWHs), and on New Oral Anticoagulants (NOACs) more recently. To summarize the comparative effectiveness of UFHs, LMWHs, and NOACs in this clinical indication, we applied Bayesian network meta-analysis to the clinical material (randomized studies) published in two previous reviews focused on this issue.

Objectives: Our end-point was a composite of venous thromboembolism and pulmonary embolism.

Materials and Methods: Our analysis was based on standard Bayesian network meta-analysis (random-effect model).

Results: The analysis included 21 randomized trials for a total of 21,805 patients. Our results showed that the degree of effectiveness did not differ among UFHs, LMWHs, and NOACs. Although some trends emerged from an in-depth analysis of these data (e.g. according to the histogram of rankings), no significant differences were found (P > 0.05). Moreover, two agents among LMWHs proved to be adequately supported by randomized trials (enoxaparin and dalteparin), while limited evidence was available for other agents of this class.

Conclusions: Our synthesis of the effectiveness data can be useful as an overall reference in this area and can also contribute to defining the place of further innovative treatments for this clinical indication.

Highlights

Fulltext

The full text is available in PDF.

References

  • 1.
    The references are available in PDF.

Copyright

© 2017, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

30
Apr
2016
Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review

Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review

Reza Ganji,
Shahram Ala,
Mohsen Aarabi,
Babak Baghery,
Ebrahim Salehifar

Ganji R, Ala S, Aarabi M, Baghery B, Salehifar E. Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review. Iran J Pharm Res. 2016;15(2):e125175. doi: https://doi.org/10.22037/ijpr.2016.1867

11
Apr
2022
Enoxaparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke

Enoxaparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke

Khanh Nguyen Duy,
Diem Thi Nguyen,
Minh Van Le,
Long Duy Le,
Huy Cong Tran,
Nhan Huu Kha
,et al.

Duy KN, Nguyen DT, Le MV, Le LD, Tran HC, et al. Enoxaparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke. J Adv Immunopharmacol. 2022;2(1):e122415. doi: https://doi.org/10.5812/tms-122415

31
Oct
2019
Comparison of Efficacy and Safety of Two Different Enoxaparin Products in Prevention of Venous Thromboembolism Following Major Obstetric-gynecological Surgeries: An Open-label Randomized Clinical Trial

Comparison of Efficacy and Safety of Two Different Enoxaparin Products in Prevention of Venous Thromboembolism Following Major Obstetric-gynecological Surgeries: An Open-label Randomized Clinical Trial

Manoochehr Abdolvand,
Ashraf Aleyasin,
Mohammad Reza Javadi,
Mohammad Solduzian,
Seyed Hossein Hosseini,
Zohreh Ziaei
,et al.

Abdolvand M, Aleyasin A, Javadi MR, Solduzian M, Hosseini SH, et al. Comparison of Efficacy and Safety of Two Different Enoxaparin Products in Prevention of Venous Thromboembolism Following Major Obstetric-gynecological Surgeries: An Open-label Randomized Clinical Trial. Iran J Pharm Res. 2019;18(4):e124707. doi: https://doi.org/10.22037/ijpr.2019.111902.13417

19
Apr
2022
Efficacy and Safety of Two Different Enoxaparin Doses for Thromboprophylaxis in Non-critically Ill Patients: A Randomized Controlled Trial

Efficacy and Safety of Two Different Enoxaparin Doses for Thromboprophylaxis in Non-critically Ill Patients: A Randomized Controlled Trial

Ilad Alavi-Darazam,
Kimia Forouhar,
Omid Moradi,
Ali Saffaei,
Sara Asadi,
Zahra Sahraei

Alavi-Darazam I, Forouhar K, Moradi O, Saffaei A, Asadi S, et al. Efficacy and Safety of Two Different Enoxaparin Doses for Thromboprophylaxis in Non-critically Ill Patients: A Randomized Controlled Trial. Iran J Pharm Res. 2022;21(1):e126555. doi: https://doi.org/10.5812/ijpr-126555

30
Sep
2014
New Oral Anticoagulants in Acute Coronary Syndrome: Is There Any Advantage Over Existing Treatments?

New Oral Anticoagulants in Acute Coronary Syndrome: Is There Any Advantage Over Existing Treatments?

Andrea Messori,
Valeria Fadda,
Roberta Gatto,
Dario Maratea,
Sabrina Trippoli

Messori A, Fadda V, Gatto R, Maratea D, Trippoli S. New Oral Anticoagulants in Acute Coronary Syndrome: Is There Any Advantage Over Existing Treatments?. Int Cardiovasc Res J. 2017;8(3):e11104. doi:

More by these authors

Andrea MessoriPubMedScholar
Sabrina TrippoliPubMedScholar
Dario MarateaPubMedScholar
Valeria FaddaPubMedScholar
Claudio MarinaiPubMedScholar
Share
Cited by
Metrics